Clinical Trial Search

Primary: Change From Baseline in the Restless Legs Syndrome Rating Scale — -14.0000; -9.7353 units on a scale — p=0.2742

Primary: Percent Increase in Glutathione (GSH) Concentrations in the ACC — 5; 0; 2 Percent change

Primary: [PCR Saliva] Percent Change From Baseline Ct Viral Targets — 5.8; 1.3 % Change from Baseline Cycle Threshold — p=0.287

Primary: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 — 0; 10.3; 8.1; 8.3 percentage of participants — p=0.056

Primary: Proportion of Patients Achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% Reduction From Baseline PASI Score). (Scores Range From 0 (Minimum) to 30…

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 20; 20; 13; 13 Participants

Primary: Change in Liver Fat Content Using Liver MRI-derived Proton Density Fat Fraction — -7.06 percentage of liver lobe fat

Primary: Objective Response Rate (ORR) — 26 Percentage of participants

Primary: Time to First Composite Asthma Exacerbations (CompEX) Event — NA; 45.4 weeks — p=0.6835

Primary: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint — 49 percentage of participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 19; 20; 20; 15 Participants

Primary: Percent Change From Baseline in Body Weight — -2.0; -0.3 Percent change — p=0.059

Primary: Incident Delirium Rate — 6; 0 Participants